Sessions will cover process mapping, cost optimisation, data-driven decision-making, cybersecurity, and sustainable manufacturing practices
No post-injection Delirium/Sedation Syndrome (PDSS) observed through 56 weeks
All drug substance for Moderna’s authorized Spikevax (COVID-19 mRNA vaccine) targeting the SARS-CoV-2 LP.8.1 variant is produced at the company’s facility in Laval, Quebec
Tezspire nearly eliminated the need for surgery, reducing surgical intervention by 98 per cent
Keytruda Qlex is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute
Collaboration matches more eligible patients, including those with rare and complex diseases, to appropriate clinical trials
Funding supports development of first-in-class pan-ROCK inhibitor ROC-101 through Phase 2a clinical testing
The inspection concluded with zero form 483 observations
Subscribe To Our Newsletter & Stay Updated
